Clinical practice guidelines for the diagnosis and treatment of diffuse glioma-related epilepsy: 2025 update.
- 2026-05
- Cancer letters 645
- Shuli Liang
- Xing Fan
- Suhui Kuang
- Gan You
- Tinghong Liu
- Jingwen Zhang
- Wei Zhang
- Yongping You
- Yanchun Deng
- Wenbin Ma
- Yuanxiang Lin
- Ruobin Qian
- Weihong Lin
- Liang Wang
- Chunqing Zhang
- Yuguang Guan
- Zhiqiang Yan
- Xuejun Yang
- Wenling Li
- Wei Yue
- Hua Zhang
- Dan Sun
- Yanhui Liu
- Zengguang Wang
- Hao Li
- Xiong Han
- Yi Wang
- Yuping Wang
- Weiping Liao
- Linbo Cai
- Guanglong Huang
- Yangmei Chen
- Juxiang Chen
- Xuewu Liu
- Jing Peng
- Ziyi Chen
- Ling Chen
- Guojun Zhang
- Jianguo Zhang
- Xiaoguang Qiu
- Guoguang Zhao
- Chuanlu Jiang
- Liangzhao Chu
- Yonggao Mou
- Liang Chen
- Suiqiang Zhu
- Anhua Wu
- Nu Zhang
- Shouwei Li
- Jinsong Wu
- Shuang Wang
- Yu Wang
- Shichuo Li
- Dong Zhou
- Tao Jiang
- PubMed: 41740829
- DOI: 10.1016/j.canlet.2026.218360
Study Design
- Type
- Review
Diffuse glioma-related epilepsy (dGRE) frequently presents with epilepsy as the initial symptom and is closely associated with tumor progression or recurrence, imposing significant social and psychological burdens on patients. The pathogenesis of dGRE is highly complex, involving both peritumoral microenvironmental mechanisms and tumor-intrinsic factors. Diagnosis requires a comprehensive approach integrating neuroimaging, EEG, molecular biomarkers, and spatial correlation between the tumor and the epileptogenic zone. Management aims to control seizures and improve prognosis. Non-enzyme-inducing anti-seizure medications (ASMs), such as levetiracetam and lacosamide, are recommended as first-line therapy, while valproic acid serves mainly as a second-line agent. Surgical resection, particularly maximal safe and supratotal removal guided by electrophysiological monitoring, significantly improves seizure outcomes. Radiotherapy, chemotherapy, and targeted agents further contribute to seizure control. The updated 2025 Chinese clinical practice guidelines incorporate recent advances in ASM use, postoperative withdrawal strategies, and multidisciplinary treatment algorithms. These updates provide an evidence-based reference for standardized diagnosis and management of dGRE.